Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics

被引:0
作者
Alyssa I. Clay-Gilmour
Shaji Kumar
S. Vincent Rajkumar
Abdul Rishi
Robert A. Kyle
Jerry A. Katzmann
David L. Murray
Aaron D. Norman
Alexandra J. Greenberg
Dirk R Larson
Megan M. O’Byrne
Susan L. Slager
Celine M. Vachon
机构
[1] Mayo Clinic,Department of Health Sciences Research
[2] Mayo Clinic,Division of Hematology
[3] Mercy Hospital,Department of Internal Medicine
[4] Mayo Clinic,Department of Laboratory Medicine and Pathology
来源
Leukemia | 2019年 / 33卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
We and others have shown increased risk of monoclonal gammopathy of undetermined significance (MGUS) in first-degree relatives of patients with multiple myeloma (MM). Whether familial risk of MGUS differs by the MM proband’s age at onset, tumor or clinical characteristics is unknown. MM and smoldering MM (SMM) cases (N = 430) were recruited from the Mayo Clinic in Rochester, Minnesota between 2005–2015. First-degree relatives over age 40 provided serum samples for evaluation of MGUS (N = 1179). Age and sex specific rates of MGUS among first-degree relatives were compared to a population-based sample. Cytogenetic subtypes were classified by Fluorescence in situ hybridization. MGUS was detected in 75 first-degree relatives for an age- and sex- adjusted prevalence of 5.8% (95% CI: 4.5–7.2). Prevalence of MGUS in first-degree relatives was 2.4 fold (95% CI: 1.9–2.9) greater than expected rates. Familial risk did not differ by proband’s age at diagnosis, gender, isotype, IgH translocation, or trisomy. This study confirms first-degree relatives of MM cases have a significantly higher risk of MGUS compared to the general population, regardless of age, gender, or tumor characteristics. In selected situations, such as multiple affected first-degree relatives, screening of first-degree relatives of MM cases could be considered for follow-up and prevention strategies.
引用
收藏
页码:499 / 507
页数:8
相关论文
共 278 条
[51]  
Wiernik PH(2015)Variants in ell2 influencing immunoglobulin levels associate with multiple myeloma Nat Commun 6 168-4
[52]  
Quinn-Laquer B(2017)Search for rare protein altering variants influencing susceptibility to multiple myeloma Oncotarget 8 177-86 e174
[53]  
Isgur Bergsagel K(1971)Familial factors relating to prognosis of leukemia and lymphoma Natl Cancer Inst Monogr 34 72-78
[54]  
Bizzaro N(2015)The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma JAMA Oncol 1 439-44
[55]  
Pasini P(2015)Determining the clinical significance of monoclonal gammopathy of undetermined significance: a seer-medicare population analysis Clin Lymphoma Myeloma Leuk 15 34-38
[56]  
Zawadzki ZA(2007)Familial multiple myeloma: report on two families and discussion of screening options Hered Cancer Clin Pract 5 undefined-undefined
[57]  
Aizawa Y(2012)Risk factors for multiple myeloma: a hospital-based case-control study in northwest china Cancer Epidemiol 36 undefined-undefined
[58]  
Kraj MA(2009)Familial myeloma and monoclonal gammopathy: a report of eight african american families Am J Hematol 84 undefined-undefined
[59]  
Haradin AR(undefined)undefined undefined undefined undefined-undefined
[60]  
Fisher B(undefined)undefined undefined undefined undefined-undefined